[Hyperhomocysteinemia in pediatric age and nutritional aspects of folates: an early cardiovascular risk factor]
- PMID: 17312847
- DOI: 10.4081/monaldi.2006.519
[Hyperhomocysteinemia in pediatric age and nutritional aspects of folates: an early cardiovascular risk factor]
Abstract
During the last decade, scientific evidence is mounting that elevated plasma levels of homocysteine are associated with an increased risk of atherosclerosis and cardiovascular ischemic events. Despite this evidence, however, there are still concerns about the mechanisms(s) by which homocysteine exerts its pro-atherogenic effect, and it is unclear whether the decreased plasma levels of homocysteine through diet or drugs may be paralleled by a reduction in cardiovascular risk. Experimental studies have shown that many possible mechanisms are implicated in the pro-atherogenic effect of homocysteine. Endothelial function is altered in subjects with hyperhomocysteinemia, and endothelial dysfunction is correlated with plasma levels of homocysteine. Exercise training reduces plasma levels of homocysteine and improves endothelial function, however without evidence of a better outcome. Larger studies are needed in order to demonstrate that the reduction of plasma levels of homocysteine by oral supplementation with folates and vitamins B6 and B12 translates into a decreased incidence of ischemic events, in particular in patients with documented coronary artery disease and ischemic encephalopathy.
Similar articles
-
DACH-LIGA homocystein (german, austrian and swiss homocysteine society): consensus paper on the rational clinical use of homocysteine, folic acid and B-vitamins in cardiovascular and thrombotic diseases: guidelines and recommendations.Clin Chem Lab Med. 2003 Nov;41(11):1392-403. doi: 10.1515/CCLM.2003.214. Clin Chem Lab Med. 2003. PMID: 14656016 Review.
-
Clinical use and rational management of homocysteine, folic acid, and B vitamins in cardiovascular and thrombotic diseases.Z Kardiol. 2004 Jun;93(6):439-53. doi: 10.1007/s00392-004-0075-3. Z Kardiol. 2004. PMID: 15252738 Review.
-
Hyperhomocysteinemia and cardiovascular risk: effect of vitamin supplementation in risk reduction.Curr Clin Pharmacol. 2010 Feb;5(1):30-6. doi: 10.2174/157488410790410551. Curr Clin Pharmacol. 2010. PMID: 20236081 Review.
-
Homocysteine and cardiovascular disease: a review of the evidence.Diab Vasc Dis Res. 2007 Jun;4(2):143-50. doi: 10.3132/dvdr.2007.033. Diab Vasc Dis Res. 2007. PMID: 17654449 Review.
-
Homocysteine lowering and cardiovascular disease risk: lost in translation.Can J Cardiol. 2007 Jul;23(9):707-10. doi: 10.1016/s0828-282x(07)70814-0. Can J Cardiol. 2007. PMID: 17622392 Free PMC article. Review.
Cited by
-
Homocysteine, MTHFR gene polymorphisms, and cardio-cerebrovascular risk.J Appl Genet. 2008;49(3):267-82. doi: 10.1007/BF03195624. J Appl Genet. 2008. PMID: 18670064 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical